Procter & Gamble
Executive Summary
Restructuring program will not disrupt prescription drug developments, company CEO Durk Jager says. P&G is on track for approvals of the anti-arrhythmia drug Stedicor (azimilide) within 12 months and an osteoporosis supplement for Actonel (risedronate) within nine months. P&G plans to establish 11 global business units to improve innovation and speed of commercialization. Restructuring will include lay offs of 15,000 employees worldwide, approximately 13.6% of P&G's 110,000-person workforce
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth